Antiphospholipid syndrome (APS) combines thrombotic (venous and/or arterial) and/or obstetrical manifestations  along with biological anomalies related to the presence of antiphospholipid antibodies Despite actual treatment recommended by international guidelines  the relapse rate in APS is high and survival is 65% at 15 years